董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Elizabeth G. O'Farrell | 女 | Director | 60 | 16.70万美元 | 未持股 | 2025-12-18 |
| Nicholas T. Curtis | 男 | Chief Executive Officer and Director | 70 | 157.66万美元 | 未持股 | 2025-12-18 |
| Todd B. Hammer | 男 | Director | 57 | 15.54万美元 | 未持股 | 2025-12-18 |
| Thomas B. Ellis | 男 | Director | 56 | 15.41万美元 | 未持股 | 2025-12-18 |
| Gary M. Winer | 男 | Director | 66 | 17.33万美元 | 未持股 | 2025-12-18 |
| William J. Link | 男 | Chairperson and Director | 79 | 未披露 | 未持股 | 2025-12-18 |
| Aimee S. Weisner | 女 | Director | 57 | 未披露 | 未持股 | 2025-12-18 |
| Richard L. Lindstrom | 男 | Director | 77 | 未披露 | 未持股 | 2025-12-18 |
| Richard L. Lindstrom | 男 | Director | 76 | 17.50万美元 | 未持股 | 2025-12-18 |
| William J. Link | 男 | Chairperson and Director | 79 | 19.38万美元 | 未持股 | 2025-12-18 |
| Aimee S. Weisner | 女 | Director | 56 | 15.58万美元 | 未持股 | 2025-12-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nicholas T. Curtis | 男 | Chief Executive Officer and Director | 70 | 157.66万美元 | 未持股 | 2025-12-18 |
| Alan B. Connaughton | 男 | Chief Operating Officer | 54 | 102.31万美元 | 未持股 | 2025-12-18 |
| Thomas R. Staab, II | 男 | Chief Financial Officer and Secretary | 58 | 80.97万美元 | 未持股 | 2025-12-18 |
董事简历
中英对照 | 中文 | 英文- Elizabeth G. O'Farrell
-
Elizabeth G. O'Farrell自2019年3月起担任Geron董事。Farrell女士自2020年12月起担任Inhibikase Therapeutics（一家创新小分子激酶抑制剂疗法以治疗神经感染和神经退行性疾病的制药公司）和LENSAR，Inc.（一家全球医疗技术公司）董事会成员，自2021年1月起。2017年12月，Farrell女士从礼来公司（Eli Lilly and Company）离开。礼来公司是一家全球性制药公司，在礼来公司担任了24年的职业生涯，她曾担任财务和公司治理方面的多个高级管理职位，最近一次担任首席采购官和全球共享服务主管，任期为2012年1月至2017年12月份。在此之前，她还担任政策和财务高级副总裁；财务高级副总裁；礼来美国首席财务官；礼来加拿大公司首席财务官；和总审计师。在加入礼来之前，Farrell女士是Boise Cascade Office Products的会计师，并在专业会计师事务所Whipple&Company和国际公共会计师事务所Price Waterhouse担任审计师。Farrell女士拥有印第安纳大学荣誉会计学士学位和管理信息系统硕士学位。
Elizabeth G. O'Farrell has served as a director of Geron since March 2019. Ms. O'Farrell also serves as a member of the board of directors of Inhibikase Therapeutics, a pharmaceutical company innovating small-molecule kinase inhibitor therapeutics for treatment of neurological infections and neurodegenerative diseases, since December 2020 and LENSAR, Inc., a global medical technology company, since January 2021. In December 2017 Ms. O'Farrell retired from a 24-year career with Eli Lilly and Company, a global pharmaceutical company, where she held several senior management positions in finance and corporate governance, most recently serving as Chief Procurement Officer and Head of Global Shared Services from January 2012 to December 2017. Prior to that position, she also served as Senior Vice President, Policy and Finance; Senior Vice President, Finance; Chief Financial Officer, Lilly USA; Chief Financial Officer, Lilly Canada; and General Auditor. Before joining Eli Lilly, Ms. O'Farrell was an accountant with Boise Cascade Office Products, and served as an auditor at Whipple & Company, a professional accountancy firm, and Price Waterhouse, an international public accounting firm. Ms. O'Farrell holds a B.S. in accounting with honors and an M.B.A. in management information systems, both from Indiana University. - Elizabeth G. O'Farrell自2019年3月起担任Geron董事。Farrell女士自2020年12月起担任Inhibikase Therapeutics（一家创新小分子激酶抑制剂疗法以治疗神经感染和神经退行性疾病的制药公司）和LENSAR，Inc.（一家全球医疗技术公司）董事会成员，自2021年1月起。2017年12月，Farrell女士从礼来公司（Eli Lilly and Company）离开。礼来公司是一家全球性制药公司，在礼来公司担任了24年的职业生涯，她曾担任财务和公司治理方面的多个高级管理职位，最近一次担任首席采购官和全球共享服务主管，任期为2012年1月至2017年12月份。在此之前，她还担任政策和财务高级副总裁；财务高级副总裁；礼来美国首席财务官；礼来加拿大公司首席财务官；和总审计师。在加入礼来之前，Farrell女士是Boise Cascade Office Products的会计师，并在专业会计师事务所Whipple&Company和国际公共会计师事务所Price Waterhouse担任审计师。Farrell女士拥有印第安纳大学荣誉会计学士学位和管理信息系统硕士学位。
- Elizabeth G. O'Farrell has served as a director of Geron since March 2019. Ms. O'Farrell also serves as a member of the board of directors of Inhibikase Therapeutics, a pharmaceutical company innovating small-molecule kinase inhibitor therapeutics for treatment of neurological infections and neurodegenerative diseases, since December 2020 and LENSAR, Inc., a global medical technology company, since January 2021. In December 2017 Ms. O'Farrell retired from a 24-year career with Eli Lilly and Company, a global pharmaceutical company, where she held several senior management positions in finance and corporate governance, most recently serving as Chief Procurement Officer and Head of Global Shared Services from January 2012 to December 2017. Prior to that position, she also served as Senior Vice President, Policy and Finance; Senior Vice President, Finance; Chief Financial Officer, Lilly USA; Chief Financial Officer, Lilly Canada; and General Auditor. Before joining Eli Lilly, Ms. O'Farrell was an accountant with Boise Cascade Office Products, and served as an auditor at Whipple & Company, a professional accountancy firm, and Price Waterhouse, an international public accounting firm. Ms. O'Farrell holds a B.S. in accounting with honors and an M.B.A. in management information systems, both from Indiana University.
- Nicholas T. Curtis
-
尼古拉斯·T·柯蒂斯是美国公民。
Nicholas T. Curtis has served as Chief Executive Officer and as a member of Board of Directors since February 2012. Prior to becoming Chief Executive Officer, Mr. Curtis served as chief commercial officer from Augt 2010 until February 2012. Before joining , Mr. Curtis was the vice president of sales and chief commercial officer of WaveTec Vision Systems, Inc., a privately held ophthalmic medical device company. Mr. Curtis served as a senior vice president of sales and marketing at STAAR Surgical Company, a publicly held company specializing in the manufacturing and marketing of ophthalmic surgery devices, from Augt 2002 until Augt 2008. Mr. Curtis has a B.S. from Northstern University. - 尼古拉斯·T·柯蒂斯是美国公民。
- Nicholas T. Curtis has served as Chief Executive Officer and as a member of Board of Directors since February 2012. Prior to becoming Chief Executive Officer, Mr. Curtis served as chief commercial officer from Augt 2010 until February 2012. Before joining , Mr. Curtis was the vice president of sales and chief commercial officer of WaveTec Vision Systems, Inc., a privately held ophthalmic medical device company. Mr. Curtis served as a senior vice president of sales and marketing at STAAR Surgical Company, a publicly held company specializing in the manufacturing and marketing of ophthalmic surgery devices, from Augt 2002 until Augt 2008. Mr. Curtis has a B.S. from Northstern University.
- Todd B. Hammer
-
托德·B·哈默是美国公民。托德·B·哈默是North Run Advisors和NR-GRI GP的成员。
Todd B. Hammer has served on Board of Directors since May 2023. Mr. Hammer has served as Co Managing Member at North Run Capital, LP ("North Run"), a public security investment firm, since December 2002. Prior to co founding North Run in 2002, Mr. Hammer was a Principal at Greenbriar Equity Group, LLC, a private equity firm, a Vice President at EnTrt Capital, LLC, a hedge fund and asset management firm, an Analyst at Baker Nye Greenblatt, LLC, an event driven hedge fund, and an Associate in the Investment Banking Division at Goldman, Sachs & Co. Mr. Hammer has served on the board of directors of Guerilla RF since Augt 2024. Mr. Hammer graduated from the University of Pennsylvania with dual degrees – a B.S. from the Wharton School and a B.A. from the College of Arts and Sciences. He also earned a J.D. from Harvard Law School. - 托德·B·哈默是美国公民。托德·B·哈默是North Run Advisors和NR-GRI GP的成员。
- Todd B. Hammer has served on Board of Directors since May 2023. Mr. Hammer has served as Co Managing Member at North Run Capital, LP ("North Run"), a public security investment firm, since December 2002. Prior to co founding North Run in 2002, Mr. Hammer was a Principal at Greenbriar Equity Group, LLC, a private equity firm, a Vice President at EnTrt Capital, LLC, a hedge fund and asset management firm, an Analyst at Baker Nye Greenblatt, LLC, an event driven hedge fund, and an Associate in the Investment Banking Division at Goldman, Sachs & Co. Mr. Hammer has served on the board of directors of Guerilla RF since Augt 2024. Mr. Hammer graduated from the University of Pennsylvania with dual degrees – a B.S. from the Wharton School and a B.A. from the College of Arts and Sciences. He also earned a J.D. from Harvard Law School.
- Thomas B. Ellis
-
Thomas B. Ellis自2023年5月起担任董事会成员。自2002年12月以来，Ellis先生一直担任公共安全投资公司North Run的联合管理成员。在2002年共同创立North Run之前，Ellis先生是私募股权公司Berkshire Partners，LLC的负责人、对冲基金和不良债务基金MHR Fund Management的分析师，以及高盛，Sachs & Co.投资银行部门的助理。Ellis先生自2024年8月起担任Guerilla RF，Inc.（OTCQX：GUER）（“Guerilla RF”）的董事会成员，并自2025年2月起担任光路技术技术公司（LPTH）的董事会成员。Ellis先生获得了普林斯顿大学的A.B.学位和哈佛法学院的法学博士学位。相信Ellis先生有资格担任董事会成员，因为他在金融方面的背景以及他在投资公司和与公司合作方面的丰富经验。
Thomas B. Ellis was appointed to Creative Realities, Inc.'s Board of Directors on November 6, 2025. Mr. Ellis has served as a Co Managing Member at North Run Capital, LP, a public security investment firm, since December 2002. Prior to co founding North Run in 2002, Mr. Ellis, was a Principal at Berkshire Partners, LLC, a private equity firm, an Analyst at MHR Fund Management, a hedge fund and distressed debt fund, and an Associate in the Investment Banking Division of Goldman, Sachs & Co. Mr. Ellis received an A.B. degree from Princeton University and a J.D. degree from Harvard Law School. Mr. Ellis has served on the board of directors of LENSAR, Inc. (Nasdaq: LNSR) since May 2023, on the board of directors of Guerilla RF, Inc. (OTCQX:GUER) since August 2024, and on the board of directors of LightPath Technologies, Inc. (Nasdaq: LPTH) since February 2025. - Thomas B. Ellis自2023年5月起担任董事会成员。自2002年12月以来，Ellis先生一直担任公共安全投资公司North Run的联合管理成员。在2002年共同创立North Run之前，Ellis先生是私募股权公司Berkshire Partners，LLC的负责人、对冲基金和不良债务基金MHR Fund Management的分析师，以及高盛，Sachs & Co.投资银行部门的助理。Ellis先生自2024年8月起担任Guerilla RF，Inc.（OTCQX：GUER）（“Guerilla RF”）的董事会成员，并自2025年2月起担任光路技术技术公司（LPTH）的董事会成员。Ellis先生获得了普林斯顿大学的A.B.学位和哈佛法学院的法学博士学位。相信Ellis先生有资格担任董事会成员，因为他在金融方面的背景以及他在投资公司和与公司合作方面的丰富经验。
- Thomas B. Ellis was appointed to Creative Realities, Inc.'s Board of Directors on November 6, 2025. Mr. Ellis has served as a Co Managing Member at North Run Capital, LP, a public security investment firm, since December 2002. Prior to co founding North Run in 2002, Mr. Ellis, was a Principal at Berkshire Partners, LLC, a private equity firm, an Analyst at MHR Fund Management, a hedge fund and distressed debt fund, and an Associate in the Investment Banking Division of Goldman, Sachs & Co. Mr. Ellis received an A.B. degree from Princeton University and a J.D. degree from Harvard Law School. Mr. Ellis has served on the board of directors of LENSAR, Inc. (Nasdaq: LNSR) since May 2023, on the board of directors of Guerilla RF, Inc. (OTCQX:GUER) since August 2024, and on the board of directors of LightPath Technologies, Inc. (Nasdaq: LPTH) since February 2025.
- Gary M. Winer
-
Gary M. Winer自2018年4月起担任董事会成员。自2015年1月以来，Winer先生担任DRC Health Care Advisors的顾问，该组织为生物制药、医疗设备和诊断健康领域的公司提供服务。从2019年4月到2021年9月收购该公司，Winer先生担任ORGENTEC Diagnostika GmbH的总裁兼首席执行官，该公司是一家自身免疫和感染疾病诊断测试的专业制造商。艾伯维公司（AbbVie，Inc.）或艾伯维（AbbVie）于2013年1月从雅培（Abbott）分离后，Winer先生担任艾伯维日本公司的首席执行官至2014年3月。在艾伯维分拆之前，Winer先生曾担任公司副总裁兼雅培日本公司总裁，在此之前曾担任雅培美国商业业务部门副总裁，以及雅培拉丁美洲和加拿大BINIS部门部门副总裁。25年来，Winer先生一直在一个国际平台上证明自己在医疗保健和生物制药工业方面的领导能力，该平台包括美国、欧洲、拉丁美洲、亚洲和日本等引人注目的市场。Winer先生目前在一家私营公司SmartHealth Catalyzer的董事会任职。Winer Previoly先生曾在HCW Biologics（纳斯达克：HCWB）的董事会任职至2025年6月，并在Bionode LLC的董事会任职至2020年6月，直至其于2025年被收购。Winer先生拥有加州州立大学金融学学士学位和Northstern大学家乐氏研究生院工商管理硕士学位。他认为Winer先生有资格担任董事会成员，因为他有领导和管理生物技术公司的经验，以及他的医疗保健工业知识和他在其他公司董事会任职的经验。
Gary M. Winer has served as a member of Board of Directors since April 2018. Since January 2015, Mr. Winer has served as a consultant for DRC Health Care Advisors, an organization that serves companies in the biopharma, medical device and diagnostic health sectors. From April 2019 until the acquisition of the company in September 2021, Mr. Winer served as the president and chief executive officer of ORGENTEC Diagnostika GmbH, a specialty manufacturer of autoimmune and infectio disease diagnostic tests. After AbbVie, Inc., or AbbVie, separated from Abbott Laboratories, or Abbott, in January 2013, Mr. Winer served as AbbVie Japan's chief executive officer until March 2014. Prior to the AbbVie spin off, Mr. Winer served as corporate vice president and president of Abbott Japan, and prior to that held positions as divisional vice president for Abbott's U.S. Commercial Operations, and as divisional vice president for Abbott's Latin America and Canada biness unit. For over 25 years, Mr. Winer has been proving his leadership abilities in the healthcare and biopharmaceutical industry on an international platform that includes such notable markets in the United States, Europe, Latin America, Asia, and Japan. Mr. Winer currently serves on the board of directors for a private company, SmartHealth Catalyzer. Mr. Winer previoly served on the Board of Directors for HCW Biologics (Nasdaq: HCWB) until June 2025 and on the Board of Directors for Bionode LLC from June 2020 until its acquisition in 2025. Mr. Winer holds a B.S. in Finance from California State University and an M.B.A. from Northwestern University's Kellogg Graduate School. - Gary M. Winer自2018年4月起担任董事会成员。自2015年1月以来，Winer先生担任DRC Health Care Advisors的顾问，该组织为生物制药、医疗设备和诊断健康领域的公司提供服务。从2019年4月到2021年9月收购该公司，Winer先生担任ORGENTEC Diagnostika GmbH的总裁兼首席执行官，该公司是一家自身免疫和感染疾病诊断测试的专业制造商。艾伯维公司（AbbVie，Inc.）或艾伯维（AbbVie）于2013年1月从雅培（Abbott）分离后，Winer先生担任艾伯维日本公司的首席执行官至2014年3月。在艾伯维分拆之前，Winer先生曾担任公司副总裁兼雅培日本公司总裁，在此之前曾担任雅培美国商业业务部门副总裁，以及雅培拉丁美洲和加拿大BINIS部门部门副总裁。25年来，Winer先生一直在一个国际平台上证明自己在医疗保健和生物制药工业方面的领导能力，该平台包括美国、欧洲、拉丁美洲、亚洲和日本等引人注目的市场。Winer先生目前在一家私营公司SmartHealth Catalyzer的董事会任职。Winer Previoly先生曾在HCW Biologics（纳斯达克：HCWB）的董事会任职至2025年6月，并在Bionode LLC的董事会任职至2020年6月，直至其于2025年被收购。Winer先生拥有加州州立大学金融学学士学位和Northstern大学家乐氏研究生院工商管理硕士学位。他认为Winer先生有资格担任董事会成员，因为他有领导和管理生物技术公司的经验，以及他的医疗保健工业知识和他在其他公司董事会任职的经验。
- Gary M. Winer has served as a member of Board of Directors since April 2018. Since January 2015, Mr. Winer has served as a consultant for DRC Health Care Advisors, an organization that serves companies in the biopharma, medical device and diagnostic health sectors. From April 2019 until the acquisition of the company in September 2021, Mr. Winer served as the president and chief executive officer of ORGENTEC Diagnostika GmbH, a specialty manufacturer of autoimmune and infectio disease diagnostic tests. After AbbVie, Inc., or AbbVie, separated from Abbott Laboratories, or Abbott, in January 2013, Mr. Winer served as AbbVie Japan's chief executive officer until March 2014. Prior to the AbbVie spin off, Mr. Winer served as corporate vice president and president of Abbott Japan, and prior to that held positions as divisional vice president for Abbott's U.S. Commercial Operations, and as divisional vice president for Abbott's Latin America and Canada biness unit. For over 25 years, Mr. Winer has been proving his leadership abilities in the healthcare and biopharmaceutical industry on an international platform that includes such notable markets in the United States, Europe, Latin America, Asia, and Japan. Mr. Winer currently serves on the board of directors for a private company, SmartHealth Catalyzer. Mr. Winer previoly served on the Board of Directors for HCW Biologics (Nasdaq: HCWB) until June 2025 and on the Board of Directors for Bionode LLC from June 2020 until its acquisition in 2025. Mr. Winer holds a B.S. in Finance from California State University and an M.B.A. from Northwestern University's Kellogg Graduate School.
- William J. Link
-
William J. Link自2017年11月起担任公司董事会成员、董事长。林克博士是两家医疗保健投资公司的共同创始人：林克博士于2016年与他人共同创立并担任Flying L Partners的管理合伙人；林克博士是Versant Ventures Management LLC或Versant Ventures的共同创始人兼董事总经理，后者成立于1999年。自1998年3月以来，林克博士还一直是风险投资公司和私募股权公司Brentwood Venture Capital的普通合伙人。Previoly，Dr. Link曾担任Chiron Vision Corporation的创始人、董事长和首席执行官，该公司是一家眼科医疗器械公司，于1997年出售给Bach & Lomb，Inc.。在加入Chiron Vision Corporation之前，Dr. Link创立并担任American Medical Optics（AMO）的总裁，AMO是美国医院供应公司的一个部门，该公司于1986年出售给Allergan。后来，他在AMO的继任公司Advanced Medical Optics的董事会任职，该公司于2009年被雅培收购。在进入医疗保健行业之前，Link博士是印第安纳大学医学院外科系的助理教授。自2017年以来，林克博士还在多家私营公司和一家上市公司Tars Pharmaceuticals，Inc.（纳斯达克：TARS）的董事会任职。Link Previoly博士于2003年至2020年5月期间担任Second Sight医疗产品（纳斯达克：EYES）的董事会成员、2009年5月至2021年5月期间担任爱德华兹生命科学 Corp.（NYSE：EW）、2001年6月至2021年12月期间担任Glaukos CorporationTERM4TERM4（NYSE：GKOS）、2015年7月至2022年3月期间担任Oyster Point Pharma, Inc.（纳斯达克：OYST）以及2017年5月至2024年7月期间担任RxSight，Inc.（丨纳斯达克纳斯达克：RXST）。林克博士在美国普渡大学获得机械工程学士、硕士和博士学位。认为林克博士具备担任董事会主席的资格是由于其作为多家医疗保健相关公司创始人的丰富经验、医学背景以及在其他公司董事会任职的经验。
William J. Link has served as a member and chairperson of Board of Directors since November 2017. Dr. Link is the co founder of two healthcare investment firms: in 2016 Dr. Link co founded and is Managing Partner of Flying L Partners, and Dr. Link is a co founder and a Managing Director of Versant Ventures Management LLC, or Versant Ventures, which was founded in 1999. Dr. Link has also been a general partner at Brentwood Venture Capital, a venture capital firm and private equity company, since March 1998. Previoly, Dr. Link served as founder, chairman, and chief executive officer of Chiron Vision Corporation, an ophthalmic medical device company which was sold to Bach & Lomb, Inc. in 1997. Before his time with Chiron Vision Corporation, Dr. Link founded and served as president of American Medical Optics, or AMO, a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the board of directors of AMO’s successor company, Advanced Medical Optics, which was acquired by Abbott in 2009. Before entering the healthcare indtry, Dr. Link was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. Dr. Link also serves on the board of directors of several private companies and one public company, Tars Pharmaceuticals, Inc. (Nasdaq: TARS), since 2017. Dr. Link previoly served on the board of directors of Second Sight Medical Products (Nasdaq: EYES) from 2003 until May 2020, Edwards Lifesciences Corp. (NYSE: EW) from May 2009 until May 2021, Glaukos Corporation (NYSE: GKOS) from June 2001 to December 2021, Oyster Point Pharma, Inc. (Nasdaq: OYST) from July 2015 until March 2022, and RxSight, Inc. (Nasdaq: RXST), from May 2017 until July 2024. Dr. Link received a B.S., an M.S. and a Ph.D. in mechanical engineering from Purdue University. believe Dr. Link is qualified to serve as chairperson of Board of Directors due to his extensive experience as a founder of multiple healthcare related companies, his medical background, and his experience serving on the board of directors of other companies. - William J. Link自2017年11月起担任公司董事会成员、董事长。林克博士是两家医疗保健投资公司的共同创始人：林克博士于2016年与他人共同创立并担任Flying L Partners的管理合伙人；林克博士是Versant Ventures Management LLC或Versant Ventures的共同创始人兼董事总经理，后者成立于1999年。自1998年3月以来，林克博士还一直是风险投资公司和私募股权公司Brentwood Venture Capital的普通合伙人。Previoly，Dr. Link曾担任Chiron Vision Corporation的创始人、董事长和首席执行官，该公司是一家眼科医疗器械公司，于1997年出售给Bach & Lomb，Inc.。在加入Chiron Vision Corporation之前，Dr. Link创立并担任American Medical Optics（AMO）的总裁，AMO是美国医院供应公司的一个部门，该公司于1986年出售给Allergan。后来，他在AMO的继任公司Advanced Medical Optics的董事会任职，该公司于2009年被雅培收购。在进入医疗保健行业之前，Link博士是印第安纳大学医学院外科系的助理教授。自2017年以来，林克博士还在多家私营公司和一家上市公司Tars Pharmaceuticals，Inc.（纳斯达克：TARS）的董事会任职。Link Previoly博士于2003年至2020年5月期间担任Second Sight医疗产品（纳斯达克：EYES）的董事会成员、2009年5月至2021年5月期间担任爱德华兹生命科学 Corp.（NYSE：EW）、2001年6月至2021年12月期间担任Glaukos CorporationTERM4TERM4（NYSE：GKOS）、2015年7月至2022年3月期间担任Oyster Point Pharma, Inc.（纳斯达克：OYST）以及2017年5月至2024年7月期间担任RxSight，Inc.（丨纳斯达克纳斯达克：RXST）。林克博士在美国普渡大学获得机械工程学士、硕士和博士学位。认为林克博士具备担任董事会主席的资格是由于其作为多家医疗保健相关公司创始人的丰富经验、医学背景以及在其他公司董事会任职的经验。
- William J. Link has served as a member and chairperson of Board of Directors since November 2017. Dr. Link is the co founder of two healthcare investment firms: in 2016 Dr. Link co founded and is Managing Partner of Flying L Partners, and Dr. Link is a co founder and a Managing Director of Versant Ventures Management LLC, or Versant Ventures, which was founded in 1999. Dr. Link has also been a general partner at Brentwood Venture Capital, a venture capital firm and private equity company, since March 1998. Previoly, Dr. Link served as founder, chairman, and chief executive officer of Chiron Vision Corporation, an ophthalmic medical device company which was sold to Bach & Lomb, Inc. in 1997. Before his time with Chiron Vision Corporation, Dr. Link founded and served as president of American Medical Optics, or AMO, a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the board of directors of AMO’s successor company, Advanced Medical Optics, which was acquired by Abbott in 2009. Before entering the healthcare indtry, Dr. Link was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. Dr. Link also serves on the board of directors of several private companies and one public company, Tars Pharmaceuticals, Inc. (Nasdaq: TARS), since 2017. Dr. Link previoly served on the board of directors of Second Sight Medical Products (Nasdaq: EYES) from 2003 until May 2020, Edwards Lifesciences Corp. (NYSE: EW) from May 2009 until May 2021, Glaukos Corporation (NYSE: GKOS) from June 2001 to December 2021, Oyster Point Pharma, Inc. (Nasdaq: OYST) from July 2015 until March 2022, and RxSight, Inc. (Nasdaq: RXST), from May 2017 until July 2024. Dr. Link received a B.S., an M.S. and a Ph.D. in mechanical engineering from Purdue University. believe Dr. Link is qualified to serve as chairperson of Board of Directors due to his extensive experience as a founder of multiple healthcare related companies, his medical background, and his experience serving on the board of directors of other companies.
- Aimee S. Weisner
-
Aimee S. isner自2021年2月起担任董事会成员。Isner女士还是一家眼科医疗技术和制药公司Glaukos Corporation（纽约证券交易所代码：GKOS）的现任董事会成员，她自2014年7月起担任该公司的董事。isner previoly女士于2022年6月至2025年6月期间在STAAR Surgical Company（纳斯达克：STAA）的董事会任职，该公司是一家领先的眼睛可植入晶状体开发商、制造商和营销商。她还曾于2019年10月至2023年1月被收购之前，在Oyster Point Pharma, Inc.（纳斯达克：OYST）的董事会任职，该公司是一家生物制药公司，专注于治疗眼表疾病的疗法。Isner女士于2011年1月至2019年7月退休期间担任公司副总裁兼爱德华兹生命科学公司总法律顾问。2009年5月至2010年12月，她从事私人执业，并担任位于南加州的公立制药和医疗器械公司的法律顾问。在此之前，从2002年6月到2009年5月，Isner女士曾在Advanced Medical Optics，Inc.（被雅培收购）担任多个职位，包括执行副总裁、行政和秘书。1998年1月至2002年6月，Isner女士曾在眼力健制药公司担任多个职务，包括副总裁、助理总法律顾问和助理秘书。伊斯内尔女士拥有加州州立大学富勒顿分校的学士学位和洛杉矶洛约拉法学院的法学博士学位，并作为O’Melveny & Myers LLP律师事务所的合伙人开始了她的法律生涯。她认为，伊斯内尔女士有资格担任董事会成员，因为她在不同医疗器械公司拥有丰富的法律和合规经验，包括对监管和报销问题、知识产权、公司治理、风险管理、公司交易、人力资源以及内部审计有深入的理解。
Aimee S. isner has served on Board of Directors since February 2021. Ms. isner is also a current member of the Board of Directors for Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company, where she has served as a Director since July 2014. Ms. isner previoly served on the Board of Directors of STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, from June 2022 to June 2025. She also served on the Board of Directors for Oyster Point Pharma, Inc. (Nasdaq: OYST), a biopharmaceutical company foced on therapies to treat ocular surface diseases, from October 2019 until its acquisition in January 2023. Ms. isner was corporate vice president, general counsel of Edwards Lifesciences Corporation from January 2011 until her retirement in July 2019. From May 2009 to December 2010, she was engaged in private practice and served as legal advisor to public pharmaceutical and medical device companies located in Southern California. Prior to this, from June 2002 to May 2009, Ms. isner served in a number of positions at Advanced Medical Optics, Inc. (acquired by Abbott Laboratories), including executive vice president, administration and secretary. From January 1998 to June 2002, Ms. isner served in a number of positions at Allergan, Inc., including vice president, assistant general counsel and assistant secretary. Ms. isner holds a B.A. from California State University, Fullerton, and a J.D. from Loyola Law School, Los Angeles, and began her legal career as an associate at the law firm of O’Melveny & Myers LLP. believe Ms. isner is qualified to serve on Board of Directors becae of her extensive in hoe legal and compliance experience with different medical device companies, including an in depth understanding of regulatory and reimbursement issues, intellectual property, corporate governance, risk management, corporate transactions, human resces, and internal audit. - Aimee S. isner自2021年2月起担任董事会成员。Isner女士还是一家眼科医疗技术和制药公司Glaukos Corporation（纽约证券交易所代码：GKOS）的现任董事会成员，她自2014年7月起担任该公司的董事。isner previoly女士于2022年6月至2025年6月期间在STAAR Surgical Company（纳斯达克：STAA）的董事会任职，该公司是一家领先的眼睛可植入晶状体开发商、制造商和营销商。她还曾于2019年10月至2023年1月被收购之前，在Oyster Point Pharma, Inc.（纳斯达克：OYST）的董事会任职，该公司是一家生物制药公司，专注于治疗眼表疾病的疗法。Isner女士于2011年1月至2019年7月退休期间担任公司副总裁兼爱德华兹生命科学公司总法律顾问。2009年5月至2010年12月，她从事私人执业，并担任位于南加州的公立制药和医疗器械公司的法律顾问。在此之前，从2002年6月到2009年5月，Isner女士曾在Advanced Medical Optics，Inc.（被雅培收购）担任多个职位，包括执行副总裁、行政和秘书。1998年1月至2002年6月，Isner女士曾在眼力健制药公司担任多个职务，包括副总裁、助理总法律顾问和助理秘书。伊斯内尔女士拥有加州州立大学富勒顿分校的学士学位和洛杉矶洛约拉法学院的法学博士学位，并作为O’Melveny & Myers LLP律师事务所的合伙人开始了她的法律生涯。她认为，伊斯内尔女士有资格担任董事会成员，因为她在不同医疗器械公司拥有丰富的法律和合规经验，包括对监管和报销问题、知识产权、公司治理、风险管理、公司交易、人力资源以及内部审计有深入的理解。
- Aimee S. isner has served on Board of Directors since February 2021. Ms. isner is also a current member of the Board of Directors for Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company, where she has served as a Director since July 2014. Ms. isner previoly served on the Board of Directors of STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, from June 2022 to June 2025. She also served on the Board of Directors for Oyster Point Pharma, Inc. (Nasdaq: OYST), a biopharmaceutical company foced on therapies to treat ocular surface diseases, from October 2019 until its acquisition in January 2023. Ms. isner was corporate vice president, general counsel of Edwards Lifesciences Corporation from January 2011 until her retirement in July 2019. From May 2009 to December 2010, she was engaged in private practice and served as legal advisor to public pharmaceutical and medical device companies located in Southern California. Prior to this, from June 2002 to May 2009, Ms. isner served in a number of positions at Advanced Medical Optics, Inc. (acquired by Abbott Laboratories), including executive vice president, administration and secretary. From January 1998 to June 2002, Ms. isner served in a number of positions at Allergan, Inc., including vice president, assistant general counsel and assistant secretary. Ms. isner holds a B.A. from California State University, Fullerton, and a J.D. from Loyola Law School, Los Angeles, and began her legal career as an associate at the law firm of O’Melveny & Myers LLP. believe Ms. isner is qualified to serve on Board of Directors becae of her extensive in hoe legal and compliance experience with different medical device companies, including an in depth understanding of regulatory and reimbursement issues, intellectual property, corporate governance, risk management, corporate transactions, human resces, and internal audit.
- Richard L. Lindstrom
-
Richard L. Lindstrom自2018年11月起担任董事会成员。Lindstrom博士是一名执业眼科医生，也是明尼苏达大学医学院眼科临床教授。他是明尼苏达州明尼阿波利斯市私人诊所Lindstrom眼科诊所的创始人和总裁。Lindstrom博士是美国眼科学会和美国白内障和屈光外科学会的成员。Lindstrom博士在明尼苏达大学医学院获得医学博士学位，并在明尼苏达大学医学院完成了眼科住院医师资格。相信Lindstrom博士有资格担任董事会成员，因为他在眼科研究方面的丰富经验以及他在白内障和屈光手术领域的领导地位。
Richard L. Lindstrom has served as a member of Board of Directors since November 2018. Dr. Lindstrom is a practicing ophthalmologist and a clinical professor of ophthalmology at the University of Minnesota Medical School. He is the founder and president of the Lindstrom Eye Clinic, a private practice in Minneapolis, Minnesota. Dr. Lindstrom is a member of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. Dr. Lindstrom received his M.D. from the University of Minnesota Medical School and completed his residency in ophthalmology at the University of Minnesota Medical School. believe Dr. Lindstrom is qualified to serve as a member of Board of Directors due to his extensive experience in the ophthalmology indtry and his leadership in the field of cataract and refractive surgery. - Richard L. Lindstrom自2018年11月起担任董事会成员。Lindstrom博士是一名执业眼科医生，也是明尼苏达大学医学院眼科临床教授。他是明尼苏达州明尼阿波利斯市私人诊所Lindstrom眼科诊所的创始人和总裁。Lindstrom博士是美国眼科学会和美国白内障和屈光外科学会的成员。Lindstrom博士在明尼苏达大学医学院获得医学博士学位，并在明尼苏达大学医学院完成了眼科住院医师资格。相信Lindstrom博士有资格担任董事会成员，因为他在眼科研究方面的丰富经验以及他在白内障和屈光手术领域的领导地位。
- Richard L. Lindstrom has served as a member of Board of Directors since November 2018. Dr. Lindstrom is a practicing ophthalmologist and a clinical professor of ophthalmology at the University of Minnesota Medical School. He is the founder and president of the Lindstrom Eye Clinic, a private practice in Minneapolis, Minnesota. Dr. Lindstrom is a member of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. Dr. Lindstrom received his M.D. from the University of Minnesota Medical School and completed his residency in ophthalmology at the University of Minnesota Medical School. believe Dr. Lindstrom is qualified to serve as a member of Board of Directors due to his extensive experience in the ophthalmology indtry and his leadership in the field of cataract and refractive surgery.
- Richard L. Lindstrom
-
Richard L. Lindstrom， 医学硕士。2004年9月起，他担任董事会成员，2002年5月起，担任TLC Vision的董事，1995年11月起，担任LaserVision Centers, Inc.的董事。1979年起，他参与眼科私人业务，并且是眼部护理服务公司Attending Surgeon of Minnesota Eye Consultants P.A。的创始人和董事。1987年起，他担任Minnesota Lions Eye Bank的助理董事。他还是多家医疗设备和制药公司的医疗顾问。2010年起，他担任Onpoint Medical Diagnostics, Inc.的董事会成员。他还是私营公司Acufocus, Inc., Wavetec Vision, RevitalVision, LLC和 Lindstrom Environmental, Inc.的董事会成员。他曾担任国际激光手术学会（International Society of Refractive Surgery）， 国际眼内植入学会（International Intraocular Implant Society），国际激光手术俱乐部（International Refractive Surgery Club）和美国白内障与激光手术学会（American Society of Cataract and Refractive Surgery）的总裁。1980至1989年，他担任明尼苏达大学（University of Minnesota）的眼科学教授，目前是明尼苏达大学眼科部门助理荣誉教授。他在明尼苏达大学获得医学博士学位、文学士学位和理学士学位。
Richard L. Lindstrom, M.D. has been a member of TearLab Corporation’s Board since September 2004. Dr. Lindstrom has served as a director of TLC Vision since 1996 and as a director of LaserVision Centers, Inc. since November 1995. Since 1979 Dr. Lindstrom has been engaged in the private practice of ophthalmology and is a founder, a director, and an attending surgeon of Minnesota Eye Consultants P.A., a provider of eye care services. Dr. Lindstrom has served as Associate Director of the Minnesota Lions Eye Bank since 1987. He is also a medical advisor for several medical device and pharmaceutical manufacturers. Dr. Lindstrom has been a director for Onpoint Medical Diagnostics, Inc. since 2010. Dr. Lindstrom is also currently on the boards of Acufocus, Inc., Wavetec Vision, RevitalVision, LLC, and Lindstrom Environmental, Inc., each of which is a private company. Dr. Lindstrom is a past President of the International Society of Refractive Surgery, the International Intraocular Implant Society, the International Refractive Surgery Club, and the American Society of Cataract and Refractive Surgery. From 1980 to 1989 he served as a Professor of Ophthalmology at the University of Minnesota, and he is currently an Adjunct Professor Emeritus in the Department of Ophthalmology at the University of Minnesota. Dr. Lindstrom received his Doctor of Medicine, Bachelor of Arts, and Bachelor of Sciences degrees from the University of Minnesota. - Richard L. Lindstrom， 医学硕士。2004年9月起，他担任董事会成员，2002年5月起，担任TLC Vision的董事，1995年11月起，担任LaserVision Centers, Inc.的董事。1979年起，他参与眼科私人业务，并且是眼部护理服务公司Attending Surgeon of Minnesota Eye Consultants P.A。的创始人和董事。1987年起，他担任Minnesota Lions Eye Bank的助理董事。他还是多家医疗设备和制药公司的医疗顾问。2010年起，他担任Onpoint Medical Diagnostics, Inc.的董事会成员。他还是私营公司Acufocus, Inc., Wavetec Vision, RevitalVision, LLC和 Lindstrom Environmental, Inc.的董事会成员。他曾担任国际激光手术学会（International Society of Refractive Surgery）， 国际眼内植入学会（International Intraocular Implant Society），国际激光手术俱乐部（International Refractive Surgery Club）和美国白内障与激光手术学会（American Society of Cataract and Refractive Surgery）的总裁。1980至1989年，他担任明尼苏达大学（University of Minnesota）的眼科学教授，目前是明尼苏达大学眼科部门助理荣誉教授。他在明尼苏达大学获得医学博士学位、文学士学位和理学士学位。
- Richard L. Lindstrom, M.D. has been a member of TearLab Corporation’s Board since September 2004. Dr. Lindstrom has served as a director of TLC Vision since 1996 and as a director of LaserVision Centers, Inc. since November 1995. Since 1979 Dr. Lindstrom has been engaged in the private practice of ophthalmology and is a founder, a director, and an attending surgeon of Minnesota Eye Consultants P.A., a provider of eye care services. Dr. Lindstrom has served as Associate Director of the Minnesota Lions Eye Bank since 1987. He is also a medical advisor for several medical device and pharmaceutical manufacturers. Dr. Lindstrom has been a director for Onpoint Medical Diagnostics, Inc. since 2010. Dr. Lindstrom is also currently on the boards of Acufocus, Inc., Wavetec Vision, RevitalVision, LLC, and Lindstrom Environmental, Inc., each of which is a private company. Dr. Lindstrom is a past President of the International Society of Refractive Surgery, the International Intraocular Implant Society, the International Refractive Surgery Club, and the American Society of Cataract and Refractive Surgery. From 1980 to 1989 he served as a Professor of Ophthalmology at the University of Minnesota, and he is currently an Adjunct Professor Emeritus in the Department of Ophthalmology at the University of Minnesota. Dr. Lindstrom received his Doctor of Medicine, Bachelor of Arts, and Bachelor of Sciences degrees from the University of Minnesota.
- William J. Link
-
William J. Link，自2016年11月起担任董事会成员。Link博士于2017年成立了Flying L Management，LLC，是管理合伙人。自1999年以来，Link博士一直担任Versant Ventures Management LLC的董事总经理和联合创始人。2009年5月起担任爱德华兹生命科学 Corp.董事会成员，2015年7月起担任Oyster Point Pharma Pharma，Inc.董事会成员，2001年6月起担任Lensar，Inc.董事会成员，2017年11月起担任TERM3，Tarsus Pharmaceuticals，Inc.董事会成员。在1999年11月共同创立Versant Ventures之前，Link博士在1998年至2020年期间是Brentwood Venture Capital的普通合伙人。1986年3月至1997年12月，Link博士是Chiron Vision Corp.的创始人、董事长和首席执行官。他还创立并担任1978年至1985年被Allergan，Inc.收购的American Medical Optics，Inc.的总裁。Link博士于2002年9月至2009年2月担任Advanced Medical Optics，Inc.董事、于2003年7月至2014年2月担任Inogen公司董事、于2003年8月至2020年5月担任Second Sight医疗产品公司董事。Link博士还曾在1973年至1976年期间担任印第安纳大学医学院外科系的助理教授。Link博士获得普渡大学机械工程学学士、硕士和博士学位。
William J. Link has served as a member of board of directors since November 2016. Dr. Link formed Flying L Management, LLC in 2017 and is the Managing Partner. Dr. Link has served as a managing director and co-founder of Versant Ventures Management LLC, a venture capital firm investing in early stage healthcare companies, since 1999. He has served as a member of the board of directors of Edwards Lifesciences Corp. since May 2009 Oyster Point Pharma, Inc. since July 2015 Glaukos, Inc. since June 2001 Lensar, Inc. since November 2017 and Tarsus Pharmaceuticals, Inc. since January 2017. Prior to co-founding Versant Ventures in November 1999 Dr. Link was a general partner at Brentwood Venture Capital from 1998 to 2020. From March 1986 to December 1997 Dr. Link was founder, chairman, and chief executive officer of Chiron Vision Corp. He also founded and served as President of American Medical Optics, Inc. acquired by Allergan, Inc. from 1978 to 1985. Dr. Link served as a director of Advanced Medical Optics, Inc. from September 2002 to February 2009 a director of Inogen, Inc. from July 2003 to February 2014 and a director of Second Sight Medical Products, Inc. from August 2003 to May 2020. Dr. Link also served as an assistant professor in the Department of Surgery at the Indiana University School of Medicine from 1973 to 1976. Dr. Link received a B.S., M.S., and a Ph.D. in mechanical engineering from Purdue University. - William J. Link，自2016年11月起担任董事会成员。Link博士于2017年成立了Flying L Management，LLC，是管理合伙人。自1999年以来，Link博士一直担任Versant Ventures Management LLC的董事总经理和联合创始人。2009年5月起担任爱德华兹生命科学 Corp.董事会成员，2015年7月起担任Oyster Point Pharma Pharma，Inc.董事会成员，2001年6月起担任Lensar，Inc.董事会成员，2017年11月起担任TERM3，Tarsus Pharmaceuticals，Inc.董事会成员。在1999年11月共同创立Versant Ventures之前，Link博士在1998年至2020年期间是Brentwood Venture Capital的普通合伙人。1986年3月至1997年12月，Link博士是Chiron Vision Corp.的创始人、董事长和首席执行官。他还创立并担任1978年至1985年被Allergan，Inc.收购的American Medical Optics，Inc.的总裁。Link博士于2002年9月至2009年2月担任Advanced Medical Optics，Inc.董事、于2003年7月至2014年2月担任Inogen公司董事、于2003年8月至2020年5月担任Second Sight医疗产品公司董事。Link博士还曾在1973年至1976年期间担任印第安纳大学医学院外科系的助理教授。Link博士获得普渡大学机械工程学学士、硕士和博士学位。
- William J. Link has served as a member of board of directors since November 2016. Dr. Link formed Flying L Management, LLC in 2017 and is the Managing Partner. Dr. Link has served as a managing director and co-founder of Versant Ventures Management LLC, a venture capital firm investing in early stage healthcare companies, since 1999. He has served as a member of the board of directors of Edwards Lifesciences Corp. since May 2009 Oyster Point Pharma, Inc. since July 2015 Glaukos, Inc. since June 2001 Lensar, Inc. since November 2017 and Tarsus Pharmaceuticals, Inc. since January 2017. Prior to co-founding Versant Ventures in November 1999 Dr. Link was a general partner at Brentwood Venture Capital from 1998 to 2020. From March 1986 to December 1997 Dr. Link was founder, chairman, and chief executive officer of Chiron Vision Corp. He also founded and served as President of American Medical Optics, Inc. acquired by Allergan, Inc. from 1978 to 1985. Dr. Link served as a director of Advanced Medical Optics, Inc. from September 2002 to February 2009 a director of Inogen, Inc. from July 2003 to February 2014 and a director of Second Sight Medical Products, Inc. from August 2003 to May 2020. Dr. Link also served as an assistant professor in the Department of Surgery at the Indiana University School of Medicine from 1973 to 1976. Dr. Link received a B.S., M.S., and a Ph.D. in mechanical engineering from Purdue University.
- Aimee S. Weisner
-
Aimee S. Weisner，自2011年1月起担任Edwards Lifesciences Corporation副总裁、总法律顾问。2009年至2010年，她从事私人执业，并担任位于南加州的公立制药和医疗器械公司的法律顾问。在此之前，从2002年到2009年，Weisner女士曾在被雅培收购的Advanced Medical Optics，Inc.担任多个职位，包括公司副总裁、总法律顾问和秘书；执行副总裁、行政、总法律顾问和秘书；以及执行副总裁、行政和秘书。从1998年到2002年，Weisner女士担任公司法律顾问和助理秘书；然后在眼力健制药公司担任副总裁、助理总法律顾问和助理秘书。Weisner女士拥有California State大学Fullerton分校的学士学位、洛杉矶洛约拉法学院的法学博士学位，并作为O’Melveny & Myers LLP律师事务所的合伙人开始了她的法律生涯。
Aimee S. Weisner has been corporate vice president, general counsel of Edwards Lifesciences Corporation since January 2011. From 2009 to 2010 she was engaged in private practice and served as legal advisor to public pharmaceutical and medical device companies located in Southern California. Prior to this, from 2002 to 2009 Ms. Weisner served in a number of positions at Advanced Medical Optics, Inc. acquired by Abbott Laboratories, including corporate vice president, general counsel and secretary; executive vice president, administration, general counsel and secretary; and executive vice president, administration and secretary. From 1998 to 2002 Ms. Weisner served as corporate counsel and assistant secretary; and then vice president, assistant general counsel and assistant secretary at Allergan, Inc. Ms. Weisner holds a B.A. from California State University, Fullerton, a J.D. from Loyola Law School, Los Angeles, and began her legal career as an associate at the law firm of O'Melveny & Myers LLP. - Aimee S. Weisner，自2011年1月起担任Edwards Lifesciences Corporation副总裁、总法律顾问。2009年至2010年，她从事私人执业，并担任位于南加州的公立制药和医疗器械公司的法律顾问。在此之前，从2002年到2009年，Weisner女士曾在被雅培收购的Advanced Medical Optics，Inc.担任多个职位，包括公司副总裁、总法律顾问和秘书；执行副总裁、行政、总法律顾问和秘书；以及执行副总裁、行政和秘书。从1998年到2002年，Weisner女士担任公司法律顾问和助理秘书；然后在眼力健制药公司担任副总裁、助理总法律顾问和助理秘书。Weisner女士拥有California State大学Fullerton分校的学士学位、洛杉矶洛约拉法学院的法学博士学位，并作为O’Melveny & Myers LLP律师事务所的合伙人开始了她的法律生涯。
- Aimee S. Weisner has been corporate vice president, general counsel of Edwards Lifesciences Corporation since January 2011. From 2009 to 2010 she was engaged in private practice and served as legal advisor to public pharmaceutical and medical device companies located in Southern California. Prior to this, from 2002 to 2009 Ms. Weisner served in a number of positions at Advanced Medical Optics, Inc. acquired by Abbott Laboratories, including corporate vice president, general counsel and secretary; executive vice president, administration, general counsel and secretary; and executive vice president, administration and secretary. From 1998 to 2002 Ms. Weisner served as corporate counsel and assistant secretary; and then vice president, assistant general counsel and assistant secretary at Allergan, Inc. Ms. Weisner holds a B.A. from California State University, Fullerton, a J.D. from Loyola Law School, Los Angeles, and began her legal career as an associate at the law firm of O'Melveny & Myers LLP.
高管简历
中英对照 | 中文 | 英文- Nicholas T. Curtis
尼古拉斯·T·柯蒂斯是美国公民。
Nicholas T. Curtis has served as Chief Executive Officer and as a member of Board of Directors since February 2012. Prior to becoming Chief Executive Officer, Mr. Curtis served as chief commercial officer from Augt 2010 until February 2012. Before joining , Mr. Curtis was the vice president of sales and chief commercial officer of WaveTec Vision Systems, Inc., a privately held ophthalmic medical device company. Mr. Curtis served as a senior vice president of sales and marketing at STAAR Surgical Company, a publicly held company specializing in the manufacturing and marketing of ophthalmic surgery devices, from Augt 2002 until Augt 2008. Mr. Curtis has a B.S. from Northstern University.- 尼古拉斯·T·柯蒂斯是美国公民。
- Nicholas T. Curtis has served as Chief Executive Officer and as a member of Board of Directors since February 2012. Prior to becoming Chief Executive Officer, Mr. Curtis served as chief commercial officer from Augt 2010 until February 2012. Before joining , Mr. Curtis was the vice president of sales and chief commercial officer of WaveTec Vision Systems, Inc., a privately held ophthalmic medical device company. Mr. Curtis served as a senior vice president of sales and marketing at STAAR Surgical Company, a publicly held company specializing in the manufacturing and marketing of ophthalmic surgery devices, from Augt 2002 until Augt 2008. Mr. Curtis has a B.S. from Northstern University.
- Alan B. Connaughton
Alan B. Connaughton自2015年4月起担任首席运营官。在成为首席运营官之前，康诺顿先生在2008年1月至2015年4月期间担任运营副总裁。康诺顿先生拥有20多年与医疗设备公司合作的经验。康诺顿先生获得了戈尔韦大学学院的学士学位、皇后大学学院的硕士学位和Rollins学院的工商管理硕士学位。
Alan B. Connaughton has served as chief operating officer since April 2015. Prior to becoming Chief Operating Officer, Mr. Connaughton was vice president of operations from January 2008 until April 2015. Mr. Connaughton has over 20 years of experience working with medical device companies. Mr. Connaughton received a B.S. from University College Galway, an M.S. from Queens University College and an M.B.A. from Rollins College.- Alan B. Connaughton自2015年4月起担任首席运营官。在成为首席运营官之前，康诺顿先生在2008年1月至2015年4月期间担任运营副总裁。康诺顿先生拥有20多年与医疗设备公司合作的经验。康诺顿先生获得了戈尔韦大学学院的学士学位、皇后大学学院的硕士学位和Rollins学院的工商管理硕士学位。
- Alan B. Connaughton has served as chief operating officer since April 2015. Prior to becoming Chief Operating Officer, Mr. Connaughton was vice president of operations from January 2008 until April 2015. Mr. Connaughton has over 20 years of experience working with medical device companies. Mr. Connaughton received a B.S. from University College Galway, an M.S. from Queens University College and an M.B.A. from Rollins College.
- Thomas R. Staab, II
Thomas R. Staab，II自2020年5月起担任首席财务官。Staab先生在加入之前，于2011年7月至2020年2月在上市的生物制药公司Biocryst医药，Inc.担任高级副总裁、首席财务官和财务主管。在加入BioCryst之前，Staab先生自2003年5月起通过2011年5月被默沙东 & Co.，Inc.收购担任Inspire Pharmaceuticals执行副总裁、首席财务官和财务主管，并于2003年通过该公司被Gilead Sciences 吉利德科学，Inc.收购担任代理首席财务官和Triangle Pharmaceuticals，Inc.的财务主管。在加入生物制药行业之前，Staab先生曾在普华永道会计师事务所（PricewaterhoeCoopers LLP）工作了八年，为多个行业的国家和跨国企业提供审计和biness咨询服务。他是一名注册会计师，并在北卡罗来纳大学教堂山分校获得BINCE Administration学士学位和会计学硕士学位。
Thomas R. Staab, II has served as Chief Financial Officer since May 2020. Before joining , Mr. Staab served as a Senior Vice President, Chief Financial Officer and Treasurer at BioCryst Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from July 2011 to February 2020. Prior to BioCryst, Mr. Staab served as Executive Vice President, Chief Financial Officer and Treasurer of Inspire Pharmaceuticals from May 2003 through its acquisition by Merck & Co., Inc. in May 2011, and acting Chief Financial Officer and Treasurer at Triangle Pharmaceuticals, Inc. through its acquisition by Gilead Sciences, Inc. in 2003. Before joining the biopharmaceutical industry, Mr. Staab spent eight years working for PricewaterhoeCoopers LLP providing audit and biness advisory services to national and multi national corporations in vario indtries. He is a Certified Public Accountant and received a B.S. in Biness Administration and a Master of Accounting from the University of North Carolina at Chapel Hill.- Thomas R. Staab，II自2020年5月起担任首席财务官。Staab先生在加入之前，于2011年7月至2020年2月在上市的生物制药公司Biocryst医药，Inc.担任高级副总裁、首席财务官和财务主管。在加入BioCryst之前，Staab先生自2003年5月起通过2011年5月被默沙东 & Co.，Inc.收购担任Inspire Pharmaceuticals执行副总裁、首席财务官和财务主管，并于2003年通过该公司被Gilead Sciences 吉利德科学，Inc.收购担任代理首席财务官和Triangle Pharmaceuticals，Inc.的财务主管。在加入生物制药行业之前，Staab先生曾在普华永道会计师事务所（PricewaterhoeCoopers LLP）工作了八年，为多个行业的国家和跨国企业提供审计和biness咨询服务。他是一名注册会计师，并在北卡罗来纳大学教堂山分校获得BINCE Administration学士学位和会计学硕士学位。
- Thomas R. Staab, II has served as Chief Financial Officer since May 2020. Before joining , Mr. Staab served as a Senior Vice President, Chief Financial Officer and Treasurer at BioCryst Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from July 2011 to February 2020. Prior to BioCryst, Mr. Staab served as Executive Vice President, Chief Financial Officer and Treasurer of Inspire Pharmaceuticals from May 2003 through its acquisition by Merck & Co., Inc. in May 2011, and acting Chief Financial Officer and Treasurer at Triangle Pharmaceuticals, Inc. through its acquisition by Gilead Sciences, Inc. in 2003. Before joining the biopharmaceutical industry, Mr. Staab spent eight years working for PricewaterhoeCoopers LLP providing audit and biness advisory services to national and multi national corporations in vario indtries. He is a Certified Public Accountant and received a B.S. in Biness Administration and a Master of Accounting from the University of North Carolina at Chapel Hill.